Drug Profile

AIC 499

Alternative Names: AIC-499

Latest Information Update: 21 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AiCuris; Ligand Pharmaceuticals
Class Antibacterials; Beta-lactams
Mechanism of Action Beta lactamase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Gram-negative infections

Most Recent Events

10 Sep 2024 Pharmacodynamics data from preclinical studies in Gram-negative infections presented at the 34th Congress of the European Society of Clinical Microbiology and Infectious gram-negative infections
12 Oct 2023 Discontinued - Phase-I for Gram-negative infections (In volunteers) in Austria (IV) (AiCuris pipeline, October 2023)
12 Oct 2023 Discontinued - Preclinical for Gram-negative infections in Germany, USA (IV) (AiCuris pipeline, October 2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com